Post-Marketing Surveillance
Showing 26 - 50 of >10,000
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease Trial (Desidustat)
Not yet recruiting
- Chronic Kidney Diseases
- Anemia of Chronic Kidney Disease
- (no location specified)
Aug 23, 2022
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance Study -
Not yet recruiting
- Biliary Tract Cancer
- (no location specified)
Apr 26, 2023
Mavacamten in Korean Symptomatic Obstructive Hypertrophic
Not yet recruiting
- Obstructive Hypertrophic Cardiomyopathy
-
Seoul, Korea, Republic ofBristol-Myers Squibb YH
Nov 23, 2023
Post Marketing Surveillance (PMS) Study of Mylotarg
Not yet recruiting
- Acute Myeloid Leukemia
- (no location specified)
Apr 12, 2022
(Special Use-results Surveillance on Long-term Use) With
Enrolling by invitation
- Adult Growth Hormone Deficiency
-
Fukuoka, Japan
- +6 more
Nov 8, 2022
STEMI - ST Elevation Myocardial Infarction, Anterior MI Trial in Dresden (PiCSO)
Not yet recruiting
- STEMI - ST Elevation Myocardial Infarction
- Anterior MI
- PiCSO
-
Dresden, GermanyHerzzentrum Dresden GmbH Universitätsklinik an der TU Dresden
Aug 23, 2022
Abiraterone Acetate in Indian Metastatic, Castration Resistant
Withdrawn
- Prostate Cancer
- Abiraterone Acetate
-
Bangalore, India
- +2 more
Aug 15, 2022
Tolvaptan in Patients With ADPKD
Active, not recruiting
- Polycystic Kidney, Autosomal Dominant
-
Tokyo, JapanOtsuka Pharmaceutical Co., Ltd.
Apr 6, 2022
Macular Degeneration (AMD) Post-marketing Surveillance in Japan
Completed
- Macular Degeneration
- Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
-
Multiple Locations, Japan(unnamed)
Jan 9, 2023
LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing
Not yet recruiting
- Breast Cancer
- (no location specified)
Jan 9, 2023
0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in
Not yet recruiting
- Post Operative Endophthalmitis
- Moxifloxacin hydrochloride ophthalmic solution
- (no location specified)
Jan 11, 2023
(Use-results Surveillance) With Esperoct®
Enrolling by invitation
- Haemophilia A
- Turoctocog alfa pegol
-
Fukuoka, Japan
- +14 more
Nov 8, 2022
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing
Not yet recruiting
- Unresectable Hepatocellular Carcinoma
- (no location specified)
Dec 19, 2022
The Medacta GMK SpheriKA Post-Marketing Surveillance Study
Recruiting
- Arthropathy
- Knee Replacement
- GMK SpheriKA
-
Saint-Jean, FranceClinique de l'Union
Jul 14, 2022
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
Recruiting
- SARS-CoV-2 Infection
-
Aichi, Japan
- +2 more
Jan 17, 2023
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
Apr 21, 2023
Mucopolysaccharidosis I Trial in Wuhan (Laronidase)
Recruiting
- Mucopolysaccharidosis I
-
Wuhan, ChinaInvestigational Site Number :1560001
Jan 15, 2023
Renal Cell Carcinoma Trial in Haifa (PROSENSE™)
Active, not recruiting
- Renal Cell Carcinoma
- PROSENSE™
-
Haifa, Israel
- +1 more
Dec 21, 2022
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
Recruiting
- Ovarian Cancer
- +3 more
-
Busan, Korea, Republic of
- +17 more
Jan 9, 2023
Diphtheria, Tetanus, Pertussis Trial in Seoul (TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and
Completed
- Diphtheria
- +3 more
- TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
-
Seoul, Korea, Republic of(unnamed)
Mar 15, 2022
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance
Not yet recruiting
- Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
- (no location specified)
Dec 16, 2022
Post-Marketing Study of Prucalopride Safety In Pregnancy
Recruiting
- Chronic Constipation
-
La Jolla, CaliforniaUniversity of California San Diego
Jul 18, 2022
